Literature DB >> 9894571

The reduced neuropil hypothesis: a circuit based model of schizophrenia.

L D Selemon1, P S Goldman-Rakic.   

Abstract

In recent years, quantitative studies of the neuropathology of schizophrenia have reignited interest in the cerebral cortex and focused attention on the cellular and subcellular constituents that may be altered in this disease. Findings have ranged from compromised circuitry in prefrontal areas to outright neuronal loss in temporal and cingulate cortices. Herein, we propose that a reduction in interneuronal neuropil in the prefrontal cortex is a prominent feature of cortical pathology in schizophrenia and review the growing evidence for this view from reports of altered neuronal density and immunohistochemical markers in various cortical regions. The emerging picture of neuropathology in schizophrenia is one of subtle changes in cellular architecture and brain circuity that nonetheless have a devastating impact on cortical function.

Entities:  

Mesh:

Year:  1999        PMID: 9894571     DOI: 10.1016/s0006-3223(98)00281-9

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  251 in total

Review 1.  Update on childhood-onset schizophrenia.

Authors:  J L Rapoport; G Inoff-Germain
Journal:  Curr Psychiatry Rep       Date:  2000-10       Impact factor: 5.285

Review 2.  Antipsychotic drugs and neuroplasticity: insights into the treatment and neurobiology of schizophrenia.

Authors:  C Konradi; S Heckers
Journal:  Biol Psychiatry       Date:  2001-11-15       Impact factor: 13.382

3.  Gene expression profiling reveals alterations of specific metabolic pathways in schizophrenia.

Authors:  Frank A Middleton; Karoly Mirnics; Joseph N Pierri; David A Lewis; Pat Levitt
Journal:  J Neurosci       Date:  2002-04-01       Impact factor: 6.167

4.  Mapping adolescent brain change reveals dynamic wave of accelerated gray matter loss in very early-onset schizophrenia.

Authors:  P M Thompson; C Vidal; J N Giedd; P Gochman; J Blumenthal; R Nicolson; A W Toga; J L Rapoport
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-25       Impact factor: 11.205

Review 5.  Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment.

Authors:  Christine Konradi; Stephan Heckers
Journal:  Pharmacol Ther       Date:  2003-02       Impact factor: 12.310

Review 6.  NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development.

Authors:  John H Krystal; D Cyril D'Souza; Daniel Mathalon; Edward Perry; Aysenil Belger; Ralph Hoffman
Journal:  Psychopharmacology (Berl)       Date:  2003-09-02       Impact factor: 4.530

Review 7.  Defects in Bioenergetic Coupling in Schizophrenia.

Authors:  Courtney R Sullivan; Sinead M O'Donovan; Robert E McCullumsmith; Amy Ramsey
Journal:  Biol Psychiatry       Date:  2017-10-24       Impact factor: 13.382

Review 8.  Treatment of cognitive deficits associated with schizophrenia: potential role of catechol-O-methyltransferase inhibitors.

Authors:  José A Apud; Daniel R Weinberger
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

9.  DNA-methyltransferase 1 mRNA is selectively overexpressed in telencephalic GABAergic interneurons of schizophrenia brains.

Authors:  M Veldic; H J Caruncho; W S Liu; J Davis; R Satta; D R Grayson; A Guidotti; E Costa
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-18       Impact factor: 11.205

Review 10.  Converging levels of analysis on a genomic hotspot for psychosis: insights from 22q11.2 deletion syndrome.

Authors:  Matthew J Schreiner; Maria T Lazaro; Maria Jalbrzikowski; Carrie E Bearden
Journal:  Neuropharmacology       Date:  2012-10-23       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.